Barinthus Biotherapeutics PLC 8-K filings

Barinthus Biotherapeutics announced its first quarter 2024 financial results and provided an update on its clinical development programs, including progress in celiac disease, HPV, and hepatitis B.

Barinthus Biotherapeutics' APOLLO trial of VTP-200 for HPV infections met its primary safety endpoint, showing positive trends in high-dose groups but no statistically significant improvement overall compared to placebo.

Barinthus Biotherapeutics announced its full year 2023 financial results, highlighting clinical progress and a strategic shift in focus.